**7. Conclusion**

Nanotechnology is still an emerging field in fungal vaccinology and pharmacology, yet there are many studies underlining its improved safety and tolerability. In fact, these innovative approaches have already replaced the original gold standard treatments for several forms of histoplasmosis disease, as outlined in this chapter.

Notwithstanding that, there are still a few therapeutic options to prevent and fight this neglected and potentially fatal disease. Therefore, the development of new drug delivery systems for the treatment and management of histoplasmosis is of utmost importance, particularly for AIDS patients.

Current investigation in antifungal drug delivery needs to put special emphasis on overcoming the challenges that deter the translation of nanoparticle-based systems into clinical practice.
